TDMS No. 20704 - 99 Test Type: 18-33 DAYS Route: GAVAGE

Study Gender:

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Resveratrol

Include 002 156 mg/kg

Include 005 1250 mg/kg

CAS Number: 501-36-0

Date Report Requested: 12/15/2010 Time Report Requested: 09:28:15 First Dose M/F: 11/13/07 / NA

Lab: VCU

F1_M3

C Number: IM20704

Lock Date: 01/29/2009

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include 001 Vehicle Control

Include 004 625 mg/kg

Male

TDMSE Version: 2.3.0

PWG Approval Date: NONE Include 003 312 mg/kg

Include 006 2500 mg/kg

TDMS No. 20704 - 99 **Test Type:** 18-33 DAYS

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Resveratrol

CAS Number: 501-36-0

Date Report Requested: 12/15/2010 Time Report Requested: 09:28:15 First Dose M/F: 11/13/07 / NA

Lab: VCU

B6C3F1 MICE MALE	Vehicle Control	156 mg/kg	312 mg/kg	625 mg/kg	1250 mg/kg	2500 mg/kg
Disposition Summary						
Animals Initially In Study Early Deaths	8	8	8	8	8	6
Survivors	•	•	•	•	•	•
Terminal Sacrifice Animals Examined Microscopically	8 8	8 8	8 8	8 8	8 8	6 6
Animais Examined Microscopically	0	0				
ALIMENTARY SYSTEM						
Intestine Large, Cecum	(8)	(8)	(8)	(8)	(8)	(6)
Intestine Large, Colon	(8)	(8)	(8)	(8)	(8)	(6)
Intestine Large, Rectum	(8)	(8)	(8)	(8)	(8)	(5)
Intestine Small, Duodenum	(8)	(8)	(8)	(8)	(8)	(6)
Intestine Small, Ileum	(8)	(8)	(8)	(8)	(8)	(6)
Intestine Small, Jejunum	(8)	(8)	(8)	(8)	(8)	(6)
Liver	(8)	(8)	(8)	(8)	(8)	(6)
Depletion Glycogen	6 (75%)	8 (100%)	3 (38%)	3 (38%)	4 (50%)	6 (100%)
Infiltration Cellular, Mixed Cell	5 (63%)	8 (100%)	5 (63%)	7 (88%)	8 (100%)	6 (100%)
Stomach, Forestomach	(8)	(8)	(8)	(8)	(8)	(6)
Stomach, Glandular	(8)	(8)	(8)	(8)	(8)	(6)
CARDIOVASCULAR SYSTEM						
None						
ENDOCRINE SYSTEM						
Adrenal Cortex	(8)	(8)	(7)	(7)	(8)	(6)
Adrenal Medulla	(7)	(8)	(7)	(7)	(8)	(6)

GENERAL BODY SYSTEM

None

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20704 - 99 **Test Type:** 18-33 DAYS

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Resveratrol CAS Number: 501-36-0

Date Report Requested: 12/15/2010 Time Report Requested: 09:28:15 First Dose M/F: 11/13/07 / NA

Lab: VCU

B6C3F1 MICE MALE	Vehicle Control	156 mg/kg	312 mg/kg	625 mg/kg	1250 mg/kg	2500 mg/kg
GENITAL SYSTEM						
None						
HEMATOPOIETIC SYSTEM						
Bone Marrow	(8)	(8)	(8)	(8)	(8)	(6)
Bronchial Associated Lymphoid Tissue	(0)	(0)	(1)	(1)	(0)	(0)
Gut Associated Lymphoid Tissue	(7)	(6)	(7)	(3)	(1)	(5)
Lymph Node, Mandibular	(7)	(8)	(8)	(6)	(8)	(5)
Cortex, Decreased Number, Lymphocyte		1 (13%)				
Paracortex, Decreased Number, Lymphocyte		1 (13%)			1 (13%)	1 (20%)
Lymph Node, Mesenteric	(8)	(8)	(8)	(7)	(8)	(6)
Popliteal Lymph Node	(3)	(7)	(5)	(6)	(4)	(3)
Spleen	(8)	(8)	(8)	(8)	(8)	(6)
Thymus	(8)	(8)	(8)	(8)	(8)	(6)
INTEGUMENTARY SYSTEM						
None						
MUSCULOSKELETAL SYSTEM						
Bone	(8)	(8)	(8)	(8)	(8)	(6)
NERVOUS SYSTEM						
None						
HOLL						

RESPIRATORY SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20704 - 99 **Test Type:** 18-33 DAYS

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Resveratrol

CAS Number: 501-36-0

Date Report Requested: 12/15/2010 Time Report Requested: 09:28:15 First Dose M/F: 11/13/07 / NA

Lab: VCU

B6C3F1 MICE MALE	Vehicle Control	156 mg/kg	312 mg/kg	625 mg/kg	1250 mg/kg	2500 mg/kg
Lung Bronchiole, Inflammation, Suppurative	(8)	(8)	(8)	(8)	(8) 1 (13%)	(6)
SPECIAL SENSES SYSTEM						
None						
URINARY SYSTEM						
Kidney Nephropathy	(8) 1 (13%)	(8)	(8)	(8)	(8)	(6) 2 (33%)

*** END OF REPORT ***